Overview

Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To show that Irbesartan improves endothelial dysfunction and the procoagulant state which are thought to be the possible mechanisms, inducing a generalized vasculopathy associated with microalbuminuria and vascular events in type II diabetic hypertensive patients
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Atenolol
Irbesartan